[Translated article] Changes in the Prevalence of Human Papillomavirus Genotypes in Genital Warts Since the Introduction of Prophylactic Vaccines

Magdaleno‐Tapial, Jorge; Hernández-Bel, P.; Salvador, José María Ortiz; Casanova-Esquembre, A.; Lorca-Spröhnle, Javier; Labrandero-Hoyos, Carolina; Peñuelas-Leal, Rodrigo; Sánchez‐Carazo, J.L.; Pérez‐Ferriols, A.

doi:10.1016/j.ad.2022.08.014

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While an ambispective observational study indicated a decline in the prevalence of HPV genotypes linked to most genital warts, which are targeted by the initial two prophylactic vaccines, there has been a rise in the occurrence of other HPV types. Moreover, there has been a slight rise in the occurrence of infections that involve multiple HPV genotypes or at least one high-risk HPV genotype [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Șandru,

Radu,

Petca

et al. 2024

Vaccines

View full text Add to dashboard Cite

Human papillomavirus (HPV) encompasses a diverse array of viruses, comprising approximately 200 serotypes that affect humans. While the majority of HPV strains are associated with benign skin or mucous membrane growths, a subset is implicated in severe health conditions, such as cervical, anal, vulvar, and vaginal cancers. Despite the established effectiveness of HPV vaccines in preventing cervical and anal carcinomas in particular, their therapeutic potential in addressing cutaneous diseases linked to diverse HPV strains remains an intriguing area of investigation. This narrative review critically examines the existing literature to assess the viability of HPV immunization as a therapeutic intervention for prevalent cutaneous conditions. These include genital and extragenital cutaneous warts, epidermodysplasia verruciformis, and keratinocyte carcinomas. The findings suggest a promising dual role for HPV vaccines in preventing and treating dermatologic conditions while emphasizing future research directions, including the immunization perspective against β-HPVs. Moreover, the presence of conflicting study outcomes underscores the imperative for larger-scale, randomized trials with well-matched control groups to validate the efficacy of HPV immunization in the dermatologic context. This review contributes valuable insights into the evolving landscape of HPV-vaccine applications in the field of dermatology.

show abstract

Section: Discussionmentioning

confidence: 99%